COMMITTED TO HEALTHIER AGING
KLOTHO THERAPEUTICS COMPANY
KLOTHO Therapeutics (KTI) is a biotechnology company developing a patent-pending Klotho protein that has great potential to redefine society’s experience with aging.
KTI has worldwide patents pending on versions of modified, recombinant Klotho that can be manufactured using standard cell culture technology.
Living Well Longer.
Klotho is produced naturally in the kidneys of humans and animals and has been shown to have a positive impact not only on kidney function but also diseases associated with aging. Leading researchers reported Klotho-deficient animals live 80% shorter and look older while animals overexpressing Klotho live 20-30% longer.
The company’s first focus is to improve the lives of millions of people who suffer with chronic kidney disease and acute kidney injury. Kidney disease is one of the major causes of death that affects up to 40 million people in the U.S. per year, with over 600,000 currently on dialysis. Today, there is no successful long-term therapy.
A virtual biotech.
Led by successful biotech startup executives, KTI operates virtually. This structure enables the company to accelerate development and human trials by redeploying the 40% a typical biotech spends on overhead. KTI is well positioned to begin these trials in two years.